Literature DB >> 29296977

ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint.

Natasha Kekre1, Joseph H Antin2.   

Abstract

Publisher's Note: This article has a companion Point by Bacigalupo. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Year:  2017        PMID： 29296977      PMCID： PMC5728595          DOI： 10.1182/bloodadvances.2016001552

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  28 in total

1.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.

Authors:  Xingmin Feng; Sachiko Kajigaya; Elena E Solomou; Keyvan Keyvanfar; Xiuli Xu; Nalini Raghavachari; Peter J Munson; Thomas M Herndon; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

2.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

Authors:  Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

3.  Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy.

Authors:  R Admiraal; J J Boelens
Journal:  Expert Opin Biol Ther       Date:  2016-03-28       Impact factor: 4.388

4.  Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.

Authors:  Irwin Walker; Tony Panzarella; Stephen Couban; Felix Couture; Gerald Devins; Mohamed Elemary; Geneviève Gallagher; Holly Kerr; John Kuruvilla; Stephanie J Lee; John Moore; Thomas Nevill; Gizelle Popradi; Jean Roy; Kirk R Schultz; David Szwajcer; Cynthia Toze; Ronan Foley
Journal:  Lancet Oncol       Date:  2015-12-24       Impact factor: 41.316

5.  Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

Authors:  Gérard Socié; Claudia Schmoor; Wolfgang A Bethge; Hellmut D Ottinger; Matthias Stelljes; Axel R Zander; Liisa Volin; Tapani Ruutu; Dominik A Heim; Rainer Schwerdtfeger; Karin Kolbe; Jiri Mayer; Johan A Maertens; Werner Linkesch; Ernst Holler; Vladimir Koza; Martin Bornhäuser; Hermann Einsele; Hans-Jochem Kolb; Hartmut Bertz; Matthias Egger; Olga Grishina; Jürgen Finke
Journal:  Blood       Date:  2011-04-05       Impact factor: 22.113

6.  Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303.

Authors:  Steven M Devine; Shelly Carter; Robert J Soiffer; Marcelo C Pasquini; Parameswaran N Hari; Anthony Stein; Hillard M Lazarus; Charles Linker; Edward A Stadtmauer; Edwin P Alyea; Carolyn A Keever-Taylor; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-12       Impact factor: 5.742

7.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Authors:  Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette Kasamon; Steven N Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

8.  Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

Authors:  Nicolaus Kröger; Carlos Solano; Christine Wolschke; Giuseppe Bandini; Francesca Patriarca; Massimo Pini; Arnon Nagler; Carmine Selleri; Antonio Risitano; Giuseppe Messina; Wolfgang Bethge; Jaime Pérez de Oteiza; Rafael Duarte; Angelo Michele Carella; Michele Cimminiello; Stefano Guidi; Jürgen Finke; Nicola Mordini; Christelle Ferra; Jorge Sierra; Domenico Russo; Mario Petrini; Giuseppe Milone; Fabio Benedetti; Marion Heinzelmann; Domenico Pastore; Manuel Jurado; Elisabetta Terruzzi; Franco Narni; Andreas Völp; Francis Ayuk; Tapani Ruutu; Francesca Bonifazi
Journal:  N Engl J Med       Date:  2016-01-07       Impact factor: 91.245

9.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Brent R Logan; Zhiwei Wang; Edwin P Alyea; Matt E Kalaycio; Richard T Maziarz; Joseph H Antin; Robert J Soiffer; Daniel J Weisdorf; J Douglas Rizzo; Mary M Horowitz; Wael Saber
Journal:  Blood       Date:  2014-04-17       Impact factor: 22.113

10.  Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation.

Authors:  Natalja Fehse; Boris Fehse; Nicolaus Kröger; Tatjana Zabelina; Petra Freiberger; William Krüger; Hartmut Kabisch; Rudolf Erttmann; Axel R Zander
Journal:  J Hematother Stem Cell Res       Date:  2003-04
View more
  10 in total

1.  Alpha-1 Antitrypsin-Expressing Mesenchymal Stromal Cells Confer a Long-Term Survival Benefit in a Mouse Model of Lethal GvHD.

Authors:  Sabine Geiger; Emrah I Ozay; Ulf Geumann; Marina K Hereth; Terese Magnusson; Sudarvili Shanthalingam; Daniela Hirsch; Stefanie Kälin; Christine Günther; Barbara A Osborne; Gregory N Tew; Felix G Hermann; Lisa M Minter
Journal:  Mol Ther       Date:  2019-05-16       Impact factor: 11.454

2.  Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study.

Authors:  Dennis L Cooper; Jacqueline Manago; Vimal Patel; Dale Schaar; Tracy Krimmel; Mary Kate McGrath; Anne Tyno; Yong Lin; Roger Strair
Journal:  Bone Marrow Transplant       Date:  2020-12-01       Impact factor: 5.483

3.  Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Authors:  Arnon Nagler; Myriam Labopin; Bhagirathbhai Dholaria; Riitta Niittyvuopio; Johan Maertens; Xavier Poiré; Jan Cornelissen; Péter Reményi; Jean Henri Bourhis; Yves Beguin; Ram Malladi; Tessa Kerre; Wilfried Schroyens; Bipin N Savani; Mohamad Mohty
Journal:  Blood Adv       Date:  2019-07-09

Review 4.  Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes.

Authors:  Julian Lindsay; Jad Othman; Madeleine R Heldman; Monica A Slavin
Journal:  Curr Opin Infect Dis       Date:  2021-12-01       Impact factor: 4.915

Review 5.  Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Authors:  Jan D Lünemann; Heinz Wiendl; Tobias Ruck; Paolo A Muraro; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2019-10-24       Impact factor: 42.937

6.  FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study

Authors:  Majid Teremmahi Ardestani; Ahmad Kazemi; Bahram Chahardouli; Saeed Mohammadi; Mohsen Nikbakht; Shahrbano Rostami; Mahdi Jalili; Mohammad Vaezi; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Turk J Haematol       Date:  2018-05-22       Impact factor: 1.831

7.  Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation.

Authors:  Taeyun Kim; Yunsuk Choi; Je-Hwan Lee; Silvia Park; Jae-Sook Ahn; Joon-Ho Moon; Ho-Jin Shin; Won Sik Lee; Dajung Kim; Ho Sup Lee
Journal:  Korean J Intern Med       Date:  2019-01-10       Impact factor: 2.884

8.  Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.

Authors:  Sara Butera; Marco Cerrano; Lucia Brunello; Chiara Maria Dellacasa; Danilo Giuseppe Faraci; Sara Vassallo; Nicola Mordini; Roberto Sorasio; Francesco Zallio; Alessandro Busca; Benedetto Bruno; Luisa Giaccone
Journal:  Ann Hematol       Date:  2021-05-04       Impact factor: 3.673

9.  Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft.

Authors:  Maxime Jullien; Thierry Guillaume; Pierre Peterlin; Alice Garnier; Amandine Le Bourgeois; Camille Debord; Beatrice Mahe; Viviane Dubruille; Soraya Wuilleme; Nicolas Blin; Cyrille Touzeau; Thomas Gastinne; Benoit Tessoulin; Yannick Le Bris; Marion Eveillard; Alix Duquesne; Philippe Moreau; Steven Le Gouill; Marie C Bene; Patrice Chevallier
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

Review 10.  Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis.

Authors:  Pascal Roland Enok Bonong; Monica Zahreddine; Chantal Buteau; Michel Duval; Louise Laporte; Jacques Lacroix; Caroline Alfieri; Helen Trottier
Journal:  Vaccines (Basel)       Date:  2021-03-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.